Aura Biosciences, Inc.
AURAHealthcare|Biotechnology|US
$6.56
+0.22 (+3.47%)
DCF Value
$0.67
Tangible Book / Share
$3.32
Cash / Share
$3.41
Clinical Trials (22)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06007690 A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Choroidal Melanoma, Indeterminate Lesions | P3 | Active | 108 | RCT, Double-blind | Bel-sar |
| NCT06643884 Suprachoroidal Administration in Subjects With Metastases to the Choroid | Eye Cancer, Primary Cancer | P2 | Recruiting | 24 | Open-label | AU-011 |
| NCT05483868 A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Non-muscle-invasive Bladder Cancer, NMIBC | P1 | Active | 55 | Open-label | AU-011 |
| NCT07421739 Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects | Choroidal Melanoma, Indeterminate Lesions | Active | 15 | — | — | |
| NCT03941379 A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | Choroidal Melanoma, Indeterminate Lesions of Eye | Active | 63 | — | — | |
| NCT07796971 High-Intensity Interval Training in Low Versus Normal Oxygen: Effects on Body Fat and Gut Health in Adults Aged 50-75 With Overweight or Obesity (HYPOXFAT) | Obesity & Overweight, Fat Mass | N/A | Recruiting | 32 | RCT, Open-label | — |
| NCT03052127 Study in Subjects With Small Primary Choroidal Melanoma | Uveal Melanoma, Ocular Melanoma | P1P2 | Completed | 57 | Open-label | Light-activated AU-011 |
| NCT04417530 Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma | Uveal Melanoma, Ocular Melanoma | P2 | Completed | 22 | Open-label | AU-011 |
| NCT06664944 Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study | Mood, Depression Disorders | Completed | 912 | — | — | |
| NCT03350308 Prediction of Risk of Hypotension in Hemodialysis | Chronical Kidney Disease, Hypotension | Completed | 60 | — | — | |
| NCT05872490 Predictors Associated With Maintaining Driving in Old Age | Aged, 80 and Over | Completed | 657 | — | — | |
| NCT05307601 Immune Response Following COVID-19 in Hemodialysis Patients | Dialysis; Complications, COVID-19 | Completed | 21 | — | — | |
| NCT05266430 Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM) | Choroidal Melanoma, Indeterminate Lesions | Terminated | 2 | — | AU-011 | |
| NCT02860312 Long Term Physical Activity for Hemodialysis Patients | End Stage Renal Disease on Hemodialysis | N/A | Unknown | 100 | RCT, Open-label | — |
| NCT05982145 The Use of Compression in Institutions and at People's Homes | Aging | Completed | 39 | — | — | |
| NCT04763811 Acceptability Study of Sensor in Elderly People's House Living Alone (Fragility Box) | Aging | Completed | 10 | — | — | |
| NCT07338968 A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma | Choroidal Melanoma, Indeterminate Lesions | By Invite | 100 | — | — | |
| NCT03940924 HIIT + RT on Body Composition and Gut Microbiota in Postmenopausal Women (PACWOMan) | Overweight, Postmenopausal Women | N/A | Completed | 17 | RCT, Single-blind | — |
| NCT04993573 Acceptability, Representations and Experiences of the COVID-19 Pandemic | Aging | Completed | 520 | — | — | |
| NCT07427407 Prospective Ultrasound Data Collection Study for AI-Based Detection of Breast Biopsy Markers | Breast Cancer | Not Yet Recruiting | 100 | — | — | |
| NCT01114789 Impact on the Proteolysis of Obesity in Dialysis | Hemodialysis Patients | N/A | Unknown | 40 | Open-label | — |
| NCT04774263 The Acceptability of a Real-time Localization for Patients and Caregivers | Disease | Completed | 19 | — | — |